Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 20

1.

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL).

Duvic M, Talpur R, Ni X, Zhang C, Hazarika P, Kelly C, Chiao JH, Reilly JF, Ricker JL, Richon VM, Frankel SR.

Blood. 2007 Jan 1;109(1):31-9. Epub 2006 Sep 7. Erratum in: Blood. 2007 Jun 15;109(12):5086.

2.
3.

Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma.

Ryan QC, Headlee D, Acharya M, Sparreboom A, Trepel JB, Ye J, Figg WD, Hwang K, Chung EJ, Murgo A, Melillo G, Elsayed Y, Monga M, Kalnitskiy M, Zwiebel J, Sausville EA.

J Clin Oncol. 2005 Jun 10;23(17):3912-22. Epub 2005 Apr 25.

PMID:
15851766
4.

Histone deacetylase inhibitors and cancer: from cell biology to the clinic.

Hess-Stumpp H.

Eur J Cell Biol. 2005 Mar;84(2-3):109-21. Review.

PMID:
15819394
5.

Depsipeptide enhances imatinib mesylate-induced apoptosis of Bcr-Abl-positive cells and ectopic expression of cyclin D1, c-Myc or active MEK abrogates this effect.

Kawano T, Horiguchi-Yamada J, Iwase S, Akiyama M, Furukawa Y, Kan Y, Yamada H.

Anticancer Res. 2004 Sep-Oct;24(5A):2705-12.

6.

A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia.

Byrd JC, Marcucci G, Parthun MR, Xiao JJ, Klisovic RB, Moran M, Lin TS, Liu S, Sklenar AR, Davis ME, Lucas DM, Fischer B, Shank R, Tejaswi SL, Binkley P, Wright J, Chan KK, Grever MR.

Blood. 2005 Feb 1;105(3):959-67. Epub 2004 Oct 5.

7.

The histone deacetylase inhibitor MS-275 induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia cells.

Lucas DM, Davis ME, Parthun MR, Mone AP, Kitada S, Cunningham KD, Flax EL, Wickham J, Reed JC, Byrd JC, Grever MR.

Leukemia. 2004 Jul;18(7):1207-14.

PMID:
15116122
8.

Determination of MS-275, a novel histone deacetylase inhibitor, in human plasma by liquid chromatography-electrospray mass spectrometry.

Hwang K, Acharya MR, Sausville EA, Zhai S, Woo EW, Venitz J, Figg WD, Sparreboom A.

J Chromatogr B Analyt Technol Biomed Life Sci. 2004 May 25;804(2):289-94.

PMID:
15081922
9.

Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously.

Kelly WK, Richon VM, O'Connor O, Curley T, MacGregor-Curtelli B, Tong W, Klang M, Schwartz L, Richardson S, Rosa E, Drobnjak M, Cordon-Cordo C, Chiao JH, Rifkind R, Marks PA, Scher H.

Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3578-88.

11.

Histone and chromatin cross-talk.

Fischle W, Wang Y, Allis CD.

Curr Opin Cell Biol. 2003 Apr;15(2):172-83. Review.

PMID:
12648673
12.

MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors.

Jaboin J, Wild J, Hamidi H, Khanna C, Kim CJ, Robey R, Bates SE, Thiele CJ.

Cancer Res. 2002 Nov 1;62(21):6108-15.

13.

Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms.

Sandor V, Bakke S, Robey RW, Kang MH, Blagosklonny MV, Bender J, Brooks R, Piekarz RL, Tucker E, Figg WD, Chan KK, Goldspiel B, Fojo AT, Balcerzak SP, Bates SE.

Clin Cancer Res. 2002 Mar;8(3):718-28.

14.

Transcriptional regulation of the transforming growth factor beta type II receptor gene by histone acetyltransferase and deacetylase is mediated by NF-Y in human breast cancer cells.

Park SH, Lee SR, Kim BC, Cho EA, Patel SP, Kang HB, Sausville EA, Nakanishi O, Trepel JB, Lee BI, Kim SJ.

J Biol Chem. 2002 Feb 15;277(7):5168-74. Epub 2001 Dec 13.

15.

Transcription regulation by histone methylation: interplay between different covalent modifications of the core histone tails.

Zhang Y, Reinberg D.

Genes Dev. 2001 Sep 15;15(18):2343-60. Review. No abstract available.

16.

MS-275, a histone deacetylase inhibitor, selectively induces transforming growth factor beta type II receptor expression in human breast cancer cells.

Lee BI, Park SH, Kim JW, Sausville EA, Kim HT, Nakanishi O, Trepel JB, Kim SJ.

Cancer Res. 2001 Feb 1;61(3):931-4.

17.

The functions of the cdk-cyclin kinase inhibitor p21WAF1.

Boulaire J, Fotedar A, Fotedar R.

Pathol Biol (Paris). 2000 Apr;48(3):190-202. Review.

PMID:
10858953
18.

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG.

J Natl Cancer Inst. 2000 Feb 2;92(3):205-16.

PMID:
10655437
19.

A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors.

Saito A, Yamashita T, Mariko Y, Nosaka Y, Tsuchiya K, Ando T, Suzuki T, Tsuruo T, Nakanishi O.

Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4592-7.

20.

Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase.

Warrell RP Jr, He LZ, Richon V, Calleja E, Pandolfi PP.

J Natl Cancer Inst. 1998 Nov 4;90(21):1621-5.

PMID:
9811311

Supplemental Content

Support Center